Empagliflozin (an SGLT2 inhibitor) alone or in combination with linagliptin (a DPP-4 inhibitor) prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

摘要

BackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of empagliflozin (selective SGLT2 inhibitor) and linagliptin (DPP-4 inhibitor) on steatohepatitis and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH) with diabetes.